The Prometheus League
Breaking News and Updates
- Abolition Of Work
- Ai
- Alt-right
- Alternative Medicine
- Antifa
- Artificial General Intelligence
- Artificial Intelligence
- Artificial Super Intelligence
- Ascension
- Astronomy
- Atheism
- Atheist
- Atlas Shrugged
- Automation
- Ayn Rand
- Bahamas
- Bankruptcy
- Basic Income Guarantee
- Big Tech
- Bitcoin
- Black Lives Matter
- Blackjack
- Boca Chica Texas
- Brexit
- Caribbean
- Casino
- Casino Affiliate
- Cbd Oil
- Censorship
- Cf
- Chess Engines
- Childfree
- Cloning
- Cloud Computing
- Conscious Evolution
- Corona Virus
- Cosmic Heaven
- Covid-19
- Cryonics
- Cryptocurrency
- Cyberpunk
- Darwinism
- Democrat
- Designer Babies
- DNA
- Donald Trump
- Eczema
- Elon Musk
- Entheogens
- Ethical Egoism
- Eugenic Concepts
- Eugenics
- Euthanasia
- Evolution
- Extropian
- Extropianism
- Extropy
- Fake News
- Federalism
- Federalist
- Fifth Amendment
- Fifth Amendment
- Financial Independence
- First Amendment
- Fiscal Freedom
- Food Supplements
- Fourth Amendment
- Fourth Amendment
- Free Speech
- Freedom
- Freedom of Speech
- Futurism
- Futurist
- Gambling
- Gene Medicine
- Genetic Engineering
- Genome
- Germ Warfare
- Golden Rule
- Government Oppression
- Hedonism
- High Seas
- History
- Hubble Telescope
- Human Genetic Engineering
- Human Genetics
- Human Immortality
- Human Longevity
- Illuminati
- Immortality
- Immortality Medicine
- Intentional Communities
- Jacinda Ardern
- Jitsi
- Jordan Peterson
- Las Vegas
- Liberal
- Libertarian
- Libertarianism
- Liberty
- Life Extension
- Macau
- Marie Byrd Land
- Mars
- Mars Colonization
- Mars Colony
- Memetics
- Micronations
- Mind Uploading
- Minerva Reefs
- Modern Satanism
- Moon Colonization
- Nanotech
- National Vanguard
- NATO
- Neo-eugenics
- Neurohacking
- Neurotechnology
- New Utopia
- New Zealand
- Nihilism
- Nootropics
- NSA
- Oceania
- Offshore
- Olympics
- Online Casino
- Online Gambling
- Pantheism
- Personal Empowerment
- Poker
- Political Correctness
- Politically Incorrect
- Polygamy
- Populism
- Post Human
- Post Humanism
- Posthuman
- Posthumanism
- Private Islands
- Progress
- Proud Boys
- Psoriasis
- Psychedelics
- Putin
- Quantum Computing
- Quantum Physics
- Rationalism
- Republican
- Resource Based Economy
- Robotics
- Rockall
- Ron Paul
- Roulette
- Russia
- Sealand
- Seasteading
- Second Amendment
- Second Amendment
- Seychelles
- Singularitarianism
- Singularity
- Socio-economic Collapse
- Space Exploration
- Space Station
- Space Travel
- Spacex
- Sports Betting
- Sportsbook
- Superintelligence
- Survivalism
- Talmud
- Technology
- Teilhard De Charden
- Terraforming Mars
- The Singularity
- Tms
- Tor Browser
- Trance
- Transhuman
- Transhuman News
- Transhumanism
- Transhumanist
- Transtopian
- Transtopianism
- Ukraine
- Uncategorized
- Vaping
- Victimless Crimes
- Virtual Reality
- Wage Slavery
- War On Drugs
- Waveland
- Ww3
- Yahoo
- Zeitgeist Movement
-
Prometheism
-
Forbidden Fruit
-
The Evolutionary Perspective
Daily Archives: May 25, 2022
What genetic sequencing can reveal about the secret lives of bees – PBS NewsHour
Posted: May 25, 2022 at 4:43 am
Bees are, in many ways, the darlings of the insect world. Not only do they play a crucial role in thriving ecosystems, but theyre also harbingers of the worsening consequences of climate change.
To bolster our knowledge of bee biology and behavior, a new effort dubbed the Beenome100 Project is building a first-of-its-kind library of dozens of different bee genomes. Researchers can use that information to tackle big picture questions like how to protect these tiny creatures, and how theyve evolved alongside us over time.
Beenome is just one of the many initiatives affiliated with the Earth BioGenome Project (EBP), an ambitious international effort to sequence the genomes of nearly 2 million named eukaryotic species. Eukaryotes have cells that contain nuclei and other organelles, setting them apart from other life forms like bacteria. This domain covers all plants, fungi, and animals, including bees.
READ MORE: World isnt meeting biodiversity goals, U.N. report finds
First launched in 2018, EBP aims to sequence the genomes of those species over the course of 10 years, housing them in a public database so that all researchers can have unfettered access to this extensive, unprecedented data. The sweeping project is largely made possible thanks to advancements in the field of genomic sequencing technology, which has made this work faster, cheaper and more accessible in recent years.
Bees face myriad threats in a warming world, including population decline, a loss of synchronicity with the flowers they pollinate and increased susceptibility to disease. In general, insects are vulnerable to climate change because being coldblooded makes them uniquely sensitive to temperature fluctuations, said Michael Branstetter, a research entomologist at the United States Department of Agriculture.
The extinction rate of insect species is eight times faster compared to mammals, birds and reptiles, according to the United Nations Environment Program, and if the total mass of insects continues to drop at its current annual rate, these creatures could vanish within a century. Bees are no exception to our own peril. Around a third of the crops we eat rely on animal pollinators, according to the USDA. Without bees, birds and other creatures, our pantries and refrigerators would look dramatically different.
If you picked any insect group to disappear, you wouldnt want to start with bees, because we would feel the effects for sure, Branstetter said.
The United States is home to approximately 4,000 native bee species, and the aim of Beenome is to help researchers answer such questions as the genetic underpinnings that make different species susceptible to climate change. The project has a goal of unlocking the blueprint for at least 100 species, and eventually sequencing more over time, said Jay Evans, a research entomologist at the USDA and co-lead of the project.
The broader Earth BioGenome Project will help map a massive branch on the tree of life, with many potential uses, like significantly improving our understanding of evolution and ecology. It will also inform research in fields like agriculture, medicine, biotechnology and more. But the reality of climate change is putting researchers feet to the fire.
Around 1 million animal and plant species face extinction, several potentially within the next few decades, due to forces like habitat loss and rising global temperatures, the United Nations estimates. That means Earth could lose up to 50 percent of its total biodiversity by 2100 without human intervention, according to the University of California, Davis.
For pollinator species, shifting temperatures and weather patterns shift also affect the natural timetables long adhered to by flowering plants a serious disadvantage to both the plant and the insects.
There are many reasons why genomes are useful tools for scientific research, Branstetter said, including assessing the genetic diversity of a species and identifying potential genomic signatures of sociality that underpin some species hive mentality. But the very real threat of losing entire species to environmental changes is also a consideration.
Should a species go extinct, its at least nice to know that weve documented the genome of that species, Branstetter added.
When it comes to pollination, some bees are generalists who will pollinate pretty much any flower they come across. Others specialize in specific botanical families or even species, and have evolved over time in ways that optimize their ability to retrieve pollen from their preferred plants.
One example of this is South Africas Rediviva bee, which specializes in the collection of oils from snapdragons. The relationship is an example of a bee adapting over time to be an ideal match for the flowers they frequent.
The spurs on the flowers that the bees stick their legs into vary in length, and theyve sort of co-evolved with the bees, Branstetter said. So the bees front legs also vary in length. That matched variation allows for greater efficiency of the pollinating process, a benefit to both the bees and the snapdragons.
Anna Childers co-leads the USDAs Ag100Pest Initiative sequencing arthropods like ticks, flies and weevils. She noted that its crucial to understand how bees, as sentinel insects of climate change, may be responding to fluctuating temperatures and seasons in order for us to protect potentially endangered species.
We kind of need to know how climate change might affect them, and having their genome is one way of learning this, she said.
So how does genetic code, gibberish to the untrained eye, help answer major questions?
Childers knows that peoples eyes tend to glaze over once you get into the alphabet soup (adenine, guanine, thymine and cytosine or A, G, T and C) that comprises genomes. Thats why she likes to use the metaphor of a map.
Genomes are like the most bare-boned map, where the basic geographic features are laid out but not much else. With a little more information, Childers said, you can start to add details like the locations of homes and businesses, or the traffic patterns of the busiest neighborhoods that differ depending on the time of day.
By bringing it all together in one place and having that map on which to place [other information,] it allows us to have a much more intricate understanding of whats happening, Childers said.
So far, members of 40 species are on their way to having their genomes sequenced. These bees were picked out of their natural environments, then frozen and sent to Hawaii-based labs tasked with extracting their DNA. It may sound counterintuitive to sacrifice the bees scientists aim to preserve, but dont worry they dont take enough individuals to harm the species as a whole.
Sample collection can be tricky first researchers have to actually find a member of the bee species theyre seeking to sample in the wild. For larger bees, a single part of their body like the thorax is usually enough to get a whole genome. But the tinier the bee, the more you need to retrieve genetic code.
WATCH: As bee populations decline, can technology help fill the gap?
For the small bees, theres only enough DNA if you do the whole bee. We just grind up wings, everything all together, Evans said.
Sometimes researchers can also take multiple bees from the same colony or location and pool them together to generate a genome, Branstetter noted.
Once DNA is extracted from Beenome bees in Hawaii, researchers there or in Mississippi (both locations have the technology) feed it to a sequencing machine in smaller portions.
You break that DNA down a little bit to maybe 20,000 base pair chunks. Then you put tags on the ends of each of those chunks, and then those are what go into this sequencing machine, Evans said.
After that, those sequenced chunks get stitched together in a process called assembly. The annotation phase comes next. Thats when a combination of researchers and automated analyses interpret stretches of genetic code to figure out which genes they correspond to.
The process, which concerns about a tenth of the total genome, cross references the genomes of other species to identify the genes that are shared across different forms of life. Other parts of the genome are assessed as well, including non-coding RNA and sites that regulate how genes are turned on.
The process of annotating is akin to noting those traffic patterns or key landmarks on a map. Once its complete, the seemingly endless series of four letters is transformed into a key that connects an organisms DNA to what researchers can observe about how a living member of the species goes about its daily life.
Bees captivate researchers for almost as many reasons as there are kinds of bees. For one, their behavior varies wildly across species. Some are social like the famously hive-minded honeybees and bumblebees but the majority lead solitary lives. Theres even variation within the same species in terms of living a social or solo life depending on external factors, noted Branstetter, who is involved with Beenome.
In the U.S., the Mojave poppy bee is native to a small, arid range across parts of Utah, Nevada and California. This tiny, solitary bee which belongs to a family that had not been sequenced previously specializes in pollinating local poppies that really only grow in certain conditions, and bloom for a short period during the spring.
Perdita meconis, otherwise known as the Mojave poppy bee, is pictured beside a dime to indicate its small size. Photo by Chelsey Ritner/USDA-ARS.
Their symbiosis is a prime example of how specialized the relationship between certain bees and plants can become, and just how crucial their mutual survival is. Both the bee and one of the flowers it frequents are under consideration for the endangered species list and face the threats of urbanization in their native habitat.
When Branstetters team sent the bees genome for sequencing, he said the result was one of the best genomes of a solitary bee generated thus far. He noted that the species unique biology and habitat checks a lot of boxes when it comes to the study of bees and their conservation.
Its a really tiny bee, so it was sort of challenging methodologically to see, Can we get a good genome from it?' he said. And its from the desert Southwest, so it covers a geographic region and a habitat that we dont have many representatives of for bees.
The researchers intend to collect more Mojave poppy bees in order to improve their understanding of the populations genetic diversity, but last year they didnt find a single specimen, illustrating just how tricky that field work can be. Branstetter hopes thats an example of bet hedging, when bees skip a season of poor, dry weather conditions so that they can reappear the following year.
Bee genomes can also help us map humans shared history with the rest of the natural world. Margarita Lpez-Uribe, an associate professor of entomology at Penn State University, worked with her team to sequence the squash bee genome, a species that specializes in the pollination of members of the cucurbita genus, including squash and pumpkins.
Although squash bees can be found across the U.S. today, they were originally native to southwestern parts of the country, plus modern-day Mexico. They happily feasted on wild cucurbita plants that Indigenous populations in those regions began domesticating 10,000 years ago. But as people migrated away from that region and the scale of agriculture increased over the course of millennia, they brought their cultivated cucurbits with them, and the squash bees followed suit.
This bee had been moving with the cultivation of crops and the movement of humans throughout North America, Lpez-Uribe said.
Squash bees are pictured collecting nectar inside a squash blossom. Photo courtesy Laura Jones.
By using a combination of different genomic information, she and her team estimated when geographically separated squash bees split off from each other. The squash bees that now live in the Northeast are genetically highly divergent, Lpez-Uribe said, compared to the ancestral populations that still live in the southwest and Mexico. That means that squash bees have gone through major adaptive processes in their journey across land and time.
Its clear that genomes can help us solve mysteries of evolution and ecology. But we can also call on them to help solve some of the most pressing crises facing humanity. Childers pointed to a beetle whose genomic sequence allowed researchers to understand how its able to break down wood. That kind of information, she noted, could help us identify more efficient ways to do the same thing in order to develop alternate fuels, or clean up environmental damage caused by catastrophes like oil spills.
Its hard to know what species were going to pluck out of the environment that lead us to the innovations that will transform the future, Childers said. Having a bank of genomes at our fingertips is key to unlocking that wealth.
View post:
What genetic sequencing can reveal about the secret lives of bees - PBS NewsHour
Posted in Genome
Comments Off on What genetic sequencing can reveal about the secret lives of bees – PBS NewsHour
SOSV’S INDIEBIO AND GENOME PROJECT-WRITE PARTNER TO FUND AND ADVISE STARTUPS – Kilgore News Herald
Posted: at 4:42 am
Will invest $250,000 in companies advancing genome engineering technology and science
PRINCETON, N.J., May 24, 2022 /PRNewswire/ -- The venture capital firm SOSV and its startup development program IndieBio, have teamed up with the Genome Project-write (GP-write), a global nonprofit genome engineering consortium, to launch the GP-write Startup Team, a project designed to vet, select, fund, and advise new ventures advancing the technology and science of writing genomes. The aim of the partnership is to improve access to R&D resources for viable startups in this space and increase visibility to their important work.
SOSV'S INDIEBIO AND GENOME PROJECT-WRITE PARTNER TO FUND AND ADVISE STARTUPSWill invest $250,000 to winning applicants
The partnership will provide GP-write companies with the unique opportunity for funding and advising from the GP-write Startup Team of world leaders. Selected companies will be invited to participate in the next IndieBio cohort to receive programming, network access, mentorship, and guidance from industrial experts, biotech founders, and patent licensing experts so the startups can quickly advance toward a next round of financing.
Investing in revolutionary technology that promises the betterment of humanity and the planet, SOSV has $1.2 billion in assets under management. From SOSV, IndieBio's pre-seed life-science startups receive a $275,000 investment (up to $500,000 or more with follow-on support) and join a four-month program that provides on-site expertise, access to modern laboratories, and an unparalleled mentor network. IndieBio's San Francisco and New York programs each run two, 15-company cohorts each per year. The first round of GP-write startup companies will join the IndieBio September 2022 cohort.
"SOSV's IndieBio and GP-write have a shared visionto expedite advances in large-scale genome editing and synthesisand believe the evolution of these technologies will lead to transformational change in personalized therapeutics," said IndieBio General Partner Stephen Chambers. "Our goal is to support developments in personalized gene and cellular therapies to drive dramatic cost reductions, create solutions for reversing climate change, and produce an entirely new class of engineered materials."
"The GP-write Startup Team includes world leaders across academia and industry with a track record of successful entrepreneurship in synthetic biology.We are thrilled to be uniting in this effort, which pairs GP-write's mission with the SOSV-IndieBio expertise in startup innovation," said Amy Cayne Schwartz, President and General Counsel of GP-write. "Translating valuable innovation from academia to the marketplace for the benefit of society at large is the impetus for this Startup Partnership."
Specifically, the Request For Proposals (RFP) is seeking to fund innovative, early stage startups advancing the science and technology of genome engineering. Some high priority areas include: Software Tools for Gene/Genome-Scale Design, Improvements in DNA Synthesis, Genome Editing (e.g. expand multiplexity and precision of DNA editing), or Chromosome and Organism Engineering. To learn more or submit a proposal before July 1, 2022, email amy@engineeringbiologycenter.org.
About SOSV
SOSV is a global venture capital firm headquartered in Princeton, NJ. The firm has more $1.2 billion in assets under management and specializes in the early stage development of deep tech companies focused on human and planetary health. SOSV operates the startup development programs HAX(hard tech), IndieBio(life sciences), Chinacceleratorand MOX (cross-border growth), and dlab(blockchain). To learn more, go tohttps://sosv.com/.
About IndieBio
SOSV's IndieBio is the leading life sciences startup program. With locations in New York City and San Francisco, IndieBio's mission is to turn scientists into entrepreneurs who can save lives and save the planet. IndieBio is devoted to building early stage startups that are solving humanity's most pressing problems with climate technology, synthetic biology, alternative foods, health tech, and much more. To learn more, go to https://indiebio.co/.
About Genome Project-write
GP-write, conceived as a sequel to The Human Genome Project, leverages advances in high throughput genome sequencing, gene editing and synthetic biology to drive dramatic cost reductions and expedite whole-genome writing and redesign. Supporting work of multi-institutional and interdisciplinary research teams engaged in broad public outreach, the organization includes nearly 300 scientists, affiliated with more than 100 institutions/companies in 17 countries. GP-write's Foundry and Startup Ecosystem is led by the GPW Industrial Advisory Board comprised of world leaders in genome editing and synthesis technologies.To learn more, follow GP-write: http://www.engineeringbiologycenter.org.
View original content:https://www.prnewswire.com/news-releases/sosvs-indiebio-and-genome-project-write-partner-to-fund-and-advise-startups-301553921.html
SOURCE SOSV
View post:
SOSV'S INDIEBIO AND GENOME PROJECT-WRITE PARTNER TO FUND AND ADVISE STARTUPS - Kilgore News Herald
Posted in Genome
Comments Off on SOSV’S INDIEBIO AND GENOME PROJECT-WRITE PARTNER TO FUND AND ADVISE STARTUPS – Kilgore News Herald
Mitochondrial genome recombination in somatic hybrids of Solanum commersonii and S. tuberosum | Scientific Reports – Nature.com
Posted: at 4:42 am
Complete mitochondrial genome assembly
The mitogenomes of St, Sc, and StSc were assembled into five to two subgenomes through de novo assembly using 5.3 to 6.6Gb PE reads. Each assembly was validated by conducting PCR analysis and sequencing (Tables S1 and S2, Fig. S1). The St mitogenome size was 756,058bp, and it was composed of five circular subgenomes of lengths 49,230 to 297,014bp. The total number of non-redundant genes was 78, consisting of 37 PCGs, 19 ORFs, 3 rRNAs, and 19 tRNAs (Table 1, Fig. S2A). The Sc mitogenome was 552,103bp in size with two subgenomes (338,427 and 213,676bp). The total number of non-redundant genes was 77, consisting of 37 PCGs, 20 ORFs, 3 rRNAs, and 17 tRNAs (Table 1, Fig. S2B). The StSc mitogenomes were 447,645bp in size with a major circular DNA of 398,439bp and a minor subgenome of 49,206bp. The total number of non-redundant genes was 77, consisting of 37 PCGs, 20 ORFs, 3 rRNAs, and 17 tRNAs (Table 1, Fig. S2C).
A total of 71 genes were shared among the three mitogenomes. Some genes were unique in each mitogenome: four ORFs (orf131, orf 190, orf 240, and orf 279), and three tRNAs (trnI-GAU, trnL-CAA, and trnV-GAC) were unique in the St mitogenome; five ORFs (orf109d, orf111, orf140, orf185, orf240) and one tRNA (trnfM-CAT) were unique in the Sc genome; and five ORFs (orf111, orf127, orf131, orf140, orf185) and one tRNA (trnV-GAC) were unique in the StSc mitogenome (Table 2).
Mitochondrial plastid DNA (MTPT) has been reported in various plants, such as Amborella trichopoda, Zea mays (maize), and Cynanchum wilfordii34,35,36. The degree of MTPT was examined by sequence comparison with the S. tuberosum plastome sequence (GenBank accession No. no. KM489056)37. Consequently, the St, Sc, and StSc mitogenomes were approximately 1.08.0%, 2.98.0%, and 3.14.0% considered as MTPT, respectively. Overall, approximately 1.08.0% were identified as MTPT (Table 1, Fig. S2).
Further, nuclear mitochondrial DNA (NUMT) has also been reported in various plants, such as Arabidopsis thaliana and Cucumis sativus (cucumber)38,39. NUMT was identified by sequence comparison with the S. tuberosum nuclear genome sequence (SolTub_3.0, https://www.ncbi.nlm.nih.gov/assembly/GCF_000226075.1/). Consequently, the St, Sc, and StSc mitogenomes were approximately 17.257.7%, 16.117.4%, and 10.116.3%, respectively, which were considered to be derived from or transferred to nuclear genomes accordingly. Overall, approximately 10.757.7% was identified as NUMTs. A total of 57.7% was identified in St subgenome 4, which has a very small genome size (Table 1, Fig. S2).
Homologous recombination (HR) can be mediated by repeat sequences in St, Sc, and StSc mitogenomes. The St, Sc, and StSc mitogenomes accounted for approximately 2.219.4%, 4.821.3%, and 5.725.9% of repeat sequences in which the repeat ratio was also positively correlated with the subgenome size (Table 1, Figs.1 and S2). The five St subgenomes exhibited diverse numbers of dispersed repeats: 300 (mitogenome coverage: 19.4%), 211 (15.2%), 41 (5.5%), 18 (2.2%), and 39 (4.9%) in each subgenome (Tables 1 and S5, Figs.1A and S2A). The two Sc subgenomes included 460 (25.9%) and 198 dispersed repeats (15.2%) (Tables 1 and S5, Figs.1B and S2B). Further, the two StSc subgenomes contained 480 (21.3%) and 39 (4.8%) dispersed repeats (Tables 1 and S5, Fig.1C and S2C). In contrast, tandem repeats were selected with adjacent sequences of at least two copies and up to 50bp. The St, Sc, and StSc mitogenomes had only 17, 20, and 16 tandem repeats, respectively (Table S6).
Chord diagram of three Solanum mitogenomes. (AC) represent the homologous regions of the subgenomes. R1 to R3 represent the large repeats that might cause homologous recombination among the corresponding subgenomes. St: S. tuberosum accession no. PT56, Sc: S. commersonii accession no. Lz3.2, StSc: somatic hybrid accession no. HA06-9.
Two large repeats (more than 1kb) were identified in the St subgenome 1. R1 was 11,916bp, and R2 was 7500bp. In contrast, St subgenome 2 had only R1, and subgenome 3 had only 1589bp of R3. Similarly, the R1 sequence co-existed in St subgenomes 1 and 2. The R2 repeat is shared between subgenomes 1 and 4 (Table S5, Figs.1 and S2), which might contribute to the HR between different subgenomes. The Sc mitogenomes had two multipartite structures, in which three large repeats of more than 1kb were identified (R1: 16,857bp, R2: 10,094bp, and R3: 1024bp), which might contribute to recombination events between subgenomes (Table S5, Figs.1 and S2). The StSc mitogenomes contain four large repeats (more than 1kb) (R1, 11,916bp; R2, 11,846bp; R3, 1643bp; and R4, 1024bp) that might contribute to subgenome reshuffling (Table S5, Figs.1 and S2).
We compared plastomes, mitogenomes, and nrDNAs among St, Sc, and StSc genomes. The StSc plastome was identical to Sc plastome37. Meanwhile, the StSc mitogenome shows a complicated structure with unique genes derived from both species (Table S3, Fig.2). Among 71 common genes, 21 PCGs (nad3, nad4, nad4L, nad5, nad6, sdh3, cox2, cox3, atp1, atp4, atp8, atp9, ccmB, rps3, rps4, rps12, rps13, rpl5, rpl10, rpl16, and mttB) were found identical across the three mitogenomes (denoted as green boxes on Fig.2) and their origin in the StSc genome could not be determined; 12 PCGs (nad1, nad2, nad7, nad9, sdh4, cob, cox1, ccmC, ccmFc, rps10, rpl2, and matR) were found identical with Sc (represented as sky-blue boxes in Fig.2) and 2 PCGs (atp6 and ccmFN) were identical with St (pink boxes in Fig.2). Therefore, it is likely that the majority of the somatic hybrid mitogenomes originated from Sc (Fig.2).
The origin of mitogenome recombination block in somatic hybrid (StSc) (A) Subgenome 1 of somatic hybrid mitogenome (B) Subgenome 2 of somatic hybrid mitogenome. The pink and sky-blue triangles on the black middle line indicate genes derived from S. tuberosum and S. commersonii, respectively. The green diamond boxes indicate genes of unknown origin.
GISH data using Sc genome probes revealed strong signals in 24 chromosomes but weak signals in the other 24 chromosomes in the StSc somatic hybrid (Fig.3A). We also assembled and compared 45S nrDNA cistron sequence of three species. For example, multiple aligned position at 191bp represents T genotype in St and C genotype in Sc. However, in StSc, it was identified that 75.6% of T and 24.4% of C were present. In conclusion, the overall 45S nrDNA sequences of StSc revealed both genotypes with average about 70 and 30 ratio for Sc and St, respectively (Fig.3B).
Detection of nuclear genome fusion in somatic hybrid. (A) GISH analysis of somatic hybrid (HA06-1 clone) using S. tuberosum specific-probes. The red signal of 24 arrows indicates the S. commersonii nuclear subgenomic distribution. (B) Schematic diagram of 45S ribosomal DNA cistron of Solanum species. StSc summary represents the percentage of St or Sc genotypes in the 45SnrDNA sequence.
In summary, St, a dihaploid of tetraploid cultivated potato, has five mitogenomes. Sc, a diploid wild potato, has two mitogenomes. Somatic hybrids developed via protoplast fusion of these two diploids contain the Sc-unique plastome37 but recombined mitogenomes and nuclear genomes derived from both St and Sc genomes (Fig.4).
Schematic diagram of mitogenome in parental species and their somatic hybrids. (A) S. tuberosum (St), (B) S. commersonii (Sc), and (C) somatic hybrid (StSc). S. tuberosum and S. commersonii have five and two subgenomes, respectively, which are fused into two subgenomes in the somatic hybrid generated by protoplast fusion. The origin of chloroplast genome in somatic hybrid has been determined based on sequence comparison among chloroplast genome sequences of parental species and that of the somatic hybrid.
A total of 35 PCGs were common across Solanaceae. The nonsynonymous substitution (Ka), synonymous substitution (Ks), and their ratios were calculated. The Ka values ranged from 0 to 0.119 with a 0.003 of median value. The nad4 and nad4L genes had the lowest Ka values, while atp6 had the highest Ka value. The Ks values ranged from 0.02 to 0.228 with a 0.01 of median value. Moreover, mttB and atp6 had the lowest and highest Ks values, respectively. Lastly, the Ka/Ks values ranged from 0 to 3.528 with a median value of 0.286 (Table S8, Fig.5A). A Ka/Ks value of more than 2 was observed due to the extremely low Ks value.
Mitochondrial gene diversity in Solanaceae family. (A) non-synonymous substitution (Ka) and synonymous substitution (Ks) values among the 12 Solanaceae species. Ka and Ks values were calculated with 35 protein-coding genes by CodeML program. (B) Variations of atp6 are shown by the phylogenetic tree and multiple comparisons of amino acid sequences. The conserved domain has been determined through NCBI BLASTP search.
Although the Ka and Ks values were generally low, ccmFc and mttB exhibited high Ka/Ks values of more than 1, indicating that these genes were positively selected during evolution (Fig.5A). Considering that atp6 showed a high mutation rate above 0.1. Ka and Ks values relative to the other genes, the amino-acid sequences corresponding to atp6 were compared among Solanaceae species, which revealed that amino acid sequences were variable at the N-terminus but conserved at the C-terminus (Fig.5B).
Phylogenetic trees were constructed using various programs, including RAxML, MEGA7, PhyML, and BEAST to examine the topology of the species. Trees treated with RAxML, PhyML, and BEAST displayed the same topology, while those treated with MEGA7 exhibited slightly different topologies (Fig. S3). In trees generated using RAxML representing an optimized topology (Figs.6 and S3), Solanaceae species were divided into two subfamilies, Solanoideae and Nicotianoideae, and the somatic hybrid exhibited a moderate branch between St and Sc. During the evolution of Solanaceae mitogenome, first, rps1 and rps19 were present in Solanaceae, however, these were omitted completely in Oleaceae. Next, rps7 was confirmed to be completely deleted in Solanaceae compared to Oleaceae. Lastly, ycf14 in all Nicotianoideae species was pseudogenized in the divergence period between Solanoideae and Nicotianoideae (Fig.6).
Phylogenetic relationship of 13 Solanaceae species using 35 protein-coding gene sequences commonly conserved in mitogenomes. The maximum likelihood tree was constructed using RAxML program with GTR++I model (based on jModelTest2) and a bootstrapping value of 1000. The bootstrap value (>=0.5) is shown on the node. Deleted genes and pseudogenes specifically within each group in the tree have been also shown by red and black boxes, respectively. Olea europaea in the Oleaceae family has been used as an out-group.
Here is the original post:
Mitochondrial genome recombination in somatic hybrids of Solanum commersonii and S. tuberosum | Scientific Reports - Nature.com
Posted in Genome
Comments Off on Mitochondrial genome recombination in somatic hybrids of Solanum commersonii and S. tuberosum | Scientific Reports – Nature.com
Second Genome Presents New Data at Digestive Disease Week (DDW) 2022 Demonstrating that SG-5-00455, a Potential First-in-Class Precision Therapeutic,…
Posted: at 4:42 am
Lead development candidate SG-5-00455 shows potential to become first in class PAI-1/2 inhibitor that directly targets mucosal healing in patients with inflammatory bowel disease (IBD)
BRISBANE, Calif., May 24, 2022 /PRNewswire/ -- Second Genome, a biotechnology company that leverages its proprietary platform to discover and develop precision therapies and biomarkers, presented data demonstrating the Company'sdevelopment candidate, SG-5-00455, improves epithelial barrier function and promotes mucosal healing by effectively inhibiting plasminogen activator inhibitor (PAI)-1/2 activity in the intestines. The data were presented at Digestive Disease Week 2022 Annual Meeting, held May 21-24 virtually and in San Diego, California.
Second Genome Logo (PRNewsfoto/Second Genome)
There is a strong correlation between the upregulation of SERPINE1 (PAI-1) and chronic inflammation in IBD. Local delivery of SG-5-00455 to the gastrointestinal mucosa of diseased mice demonstrated efficacy by inhibiting PAI-1 activity, which in excessive amounts adversely impacts wound healing, immune cell modulation and tissue remodeling. By selectively targeting the PAI-1 pathway at the mucosa, SG-5-00455 improves epithelial barrier function by regulating extracellular matrix production and reducing profibrotic inflammation. SG-5-00455 demonstrates the potential to directly target mucosal healing, a key therapeutic goal in the treatment of IBD," said Joseph Dal Proto, Ph.D. "SG-5-00455 has the potential to become a first-in-class treatment for patients with IBD in which mucosal healing is inadequately addressed by current standards of care."
This data was presented during a poster session at DDW 2022. The information is provided below:
Session Title: Non-Immune Cells in Intestinal Inflammation: Epithelium and StromaAbstract Number: 3698252Title: Identification and Development of a 1st in Class Naturally-Derived Protein that Drives Mucosal Healing and is Orally Delivered by an Engineered Cellular Therapy Targeting the Gastro-Intestinal Tract
Story continues
In addition to SG-5-00455, Second Genome has presented data on the identification of immunomodulatory peptides with therapeutic potential using their proprietary technology-enabled platform (abstract number: 3699744) which was presented during another poster session at DDW 2022.
SG-5-00455 is an orally delivered, engineered biotherapeutic modulator of the PAI1/2 pathway that is designed to work locally within the gastrointestinal tract to promote mucosal healing and improve barrier function in IBD patients. In vitro, SG-5-00455 demonstrated direct binding to PAI-1, functional inhibition of PAI-1/2 function and improvement in epithelial barrier function. In pre-clinical colitis models, oral administration of SG-5-00455 reduced pathology scores for inflammation and restored barrier function levels, as well as improved dysregulated tissue repair and fibrosis-associated gene expression and proteins levels. Mechanism of action studies revealed interaction with, and modulation of, fibrinolysis pathway members, which were found to be upregulated in IBD patient samples in multiple clinical cohorts. This will provide the basis for a potential biomarker to identify patients likely to respond to SG-5-00455. SG-5-00455 is currently in IND-enabling studies, and the Company anticipates filing an investigational new drug (IND) application with the U.S. FDA late 2022.
The SG-5-00455 poster (#3698252) entitled, "Identification and Development of a 1st in Class Naturally-Derived Protein that Drives Mucosal Healing and is Orally Delivered by an Engineered Cellular Therapy Targeting the Gastro-Intestinal Tract," and the poster on the identification of immunomodulatory peptides utilizing our proprietary technology-enabled drug discovery platform (#3699744) will be made available on the Company's website at https://www.secondgenome.com/events/.
About Second Genome
Second Genome is a biotechnology company that leverages its proprietary technology-enabled platform to discover and develop transformational precision therapies based on novel microbial genetic insights. We built a proprietary drug discovery platform with machine-learning analytics, customized protein engineering techniques, phage library screening, mass spec analysis and gene-editing that we couple with traditional drug development approaches to progress the development of precision therapies for wide-ranging diseases. Second Genome is advancing lead programs in IBD and cancer into IND-enabling studies. We also collaborate with industry, academic and governmental partners to leverage our platform and data science capabilities. We hold a strategic collaboration with Gilead Sciences, Inc., utilizing our proprietary platform and comprehensive data sets to identify novel biomarkers associated with clinical response to Gilead's investigational medicines. We also hold a strategic collaboration with Pfizer (formerly Arena Pharmaceuticals) to identify microbiome biomarkers associated with clinical response for their lead program in gastroenterology, etrasimod. For more information, please visit http://www.secondgenome.com.
Investor / Media Contact:650-440-4606partnering@secondgenome.com
Cision
View original content to download multimedia:https://www.prnewswire.com/news-releases/second-genome-presents-new-data-at-digestive-disease-week-ddw-2022-demonstrating-that-sg-5-00455-a-potential-first-in-class-precision-therapeutic-improves-epithelial-barrier-function-and-promotes-mucosal-healing-in-inflammator-301553343.html
SOURCE Second Genome
Continue reading here:
Second Genome Presents New Data at Digestive Disease Week (DDW) 2022 Demonstrating that SG-5-00455, a Potential First-in-Class Precision Therapeutic,...
Posted in Genome
Comments Off on Second Genome Presents New Data at Digestive Disease Week (DDW) 2022 Demonstrating that SG-5-00455, a Potential First-in-Class Precision Therapeutic,…
UF scientists may have found a way to more efficiently apply genome editing to plant breeding – hortidaily.com
Posted: at 4:42 am
New research led by a University of Florida scientist shows a development regulator can help plants grow. In the bigger picture, the studys results also may help genome editing and, as a result, plant breeding.
Development regulators are genes that regulate plant development and growth. UF/IFAS scientists have discovered that one such gene can help deliver DNA into a plant to promote shoot growth from either a stem of a whole plant or young leaves cultured in a petri dish.
The study shows that injecting a plant developmental regulator known as PLT5 into the stem helps some snapdragons and tomatoes grow into new shoots. In addition, scientists found that the PLT5 can help young leaves or petioles of cabbages grow into a whole plant after culturing them in the petri dish.
Generally, it is extremely difficult for cells from some plants to grow into whole plants from a tissue culture, said Alfred Huo, an assistant professor of horticultural sciences at the UF/IFAS Mid-Florida Research and Education Center. By applying PLT5, scientists can more effectively deliver genes or DNA fragments into plant cells, which means plants can grow from the cellular level to adulthood more efficiently.
This research can help scientists address some questions in basic plant breeding, including how to get certain genes into plants, Huo said. It can also help scientists as they apply genome editing to many plant species.
This finding can accelerate a breeding program, Huo said. You want to use genome editing for plant breeding. But you need to deliver a genome editing toolbox into plants to make the editing happen. With this process, scientists can eventually create some desirable traits in plants and develop new cultivars. In this case, the PLT5 regulator can help deliver this toolbox and help grow young leaves or stems into new plants carrying these desirable traits.
More than 20 scientists across Florida including Huo are part of the UF/IFAS Plant Breeding team. They develop new varieties of citrus, tomatoes, strawberries, blueberries, cattle forages, peanuts, sugarcane, ornamental plants, and more.
Source: ifas.ufl.edu
Posted in Genome
Comments Off on UF scientists may have found a way to more efficiently apply genome editing to plant breeding – hortidaily.com
Genome-wide identification of carbapenem-resistant Gram-negative bacterial (CR-GNB) isolates retrieved from hospitalized patients in Bihar, India |…
Posted: at 4:42 am
Katiyar, A. et al. Genomic profiling of antimicrobial resistance genes in clinical isolates of Salmonella typhi from patients infected with typhoid fever in India. Sci. Rep. 10, 8299 (2020).
ADS CAS PubMed PubMed Central Article Google Scholar
Nordmann, P. & Poirel, L. Epidemiology and diagnostics of carbapenem resistance in Gram-negative bacteria. Clin. Infect. Dis. 69, S521S528 (2019).
CAS PubMed PubMed Central Article Google Scholar
Manandhar, S. et al. A high prevalence of multi-drug resistant Gram-negative bacilli in a Nepali tertiary care hospital and associated widespread distribution of Extended-Spectrum Beta-Lactamase (ESBL) and carbapenemase-encoding genes. Ann. Clin. Microbiol. Antimicrob. 19, 48 (2020).
CAS PubMed PubMed Central Article Google Scholar
Wyres, K. L. et al. Genomic surveillance for hypervirulence and multi-drug resistance in invasive Klebsiella pneumoniae from South and Southeast Asia. Genome Med. 12, 11 (2020).
CAS PubMed PubMed Central Article Google Scholar
World Health Organization. Guidelines for the Prevention and Control of Carbapenem-Resistant Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa in Health Care Facilities (WHO, 2017).
Google Scholar
Zavascki, A. P., Bulitta, J. B. & Landersdorfer, C. B. Combination therapy for carbapenem-resistant Gram-negative bacteria. Expert Rev. Anti. Infect. Ther. 11, 13331353 (2013).
CAS PubMed Article Google Scholar
Karampatakis, T. et al. Molecular epidemiology of endemic carbapenem-resistant Gram-negative bacteria in an intensive care unit. Microb. Drug Resist. 25, 712716 (2018).
PubMed Article CAS Google Scholar
Nair, S. et al. ESBL-producing strains isolated from imported cases of enteric fever in England and Wales reveal multiple chromosomal integrations of blaCTX-M-15 in XDR Salmonella Typhi. J. Antimicrob. Chemother. 76, 14591466 (2021).
CAS PubMed Article Google Scholar
Zagui, G. S. et al. Gram-negative bacteria carrying -lactamase encoding genes in hospital and urban wastewater in Brazil. Environ. Monit. Assess. 192, 376 (2020).
CAS PubMed Article Google Scholar
Elbadawi, H. S. et al. Detection and characterization of carbapenem resistant Gram negative bacilli isolates recovered from hospitalized patients at Soba University Hospital, Sudan. BMC Microbiol. 21, 136 (2021).
CAS PubMed PubMed Central Article Google Scholar
Sawa, T., Kooguchi, K. & Moriyama, K. Molecular diversity of extended-spectrum -lactamases and carbapenemases, and antimicrobial resistance. J. Intensive Care 8, 13 (2020).
PubMed PubMed Central Article Google Scholar
Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: 22th Informational Supplement (CLSI, 2012).
Google Scholar
Altoparlak, U., Aktas, F., Celebi, D., Ozkurt, Z. & Akcay, M. N. Prevalence of metallo-beta-lactamase among Pseudomonas aeruginosa and Acinetobacter baumannii isolated from burn wounds and in vitro activities of antibiotic combinations against these isolates. Burns 31(6), 707710 (2005).
PubMed Article Google Scholar
Song, W. et al. Detection of extended spectrum -lactamases by using boronic-acid as an AmpC -lactamase inhibitor in clinical isolates of Klebsiella spp. and Escherichia coli. J. Clin. Microbiol. 45, 118084 (2007).
CAS PubMed PubMed Central Article Google Scholar
Lee, K. et al. Modified Hodge and EDTA-disk synergy tests to screen metallo--lactamase-producing strains of Pseudomonas and Acinetobactet species. Clin. Microbiol. Infect. 7, 8891 (2001).
CAS PubMed Article Google Scholar
Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: A flexible trimmer for Illumina sequence data. Bioinformatics 30, 21142120 (2014).
CAS PubMed PubMed Central Article Google Scholar
Zerbino, D. R. & Birney, E. Velvet: Algorithms for de novo short read assembly using de Bruijn graphs. Genome Res. 18, 821829 (2008).
CAS PubMed PubMed Central Article Google Scholar
Gurevich, A., Saveliev, V., Vyahhi, N. & Tesler, G. QUAST: Quality assessment tool for genome assemblies. Bioinformatics 29, 10721075. https://doi.org/10.1093/bioinformatics/btt086 (2013).
CAS Article PubMed PubMed Central Google Scholar
Seemann, T. Prokka: Rapid prokaryotic genome annotation. Bioinformatics 30, 20682069. https://doi.org/10.1093/bioinformatics/btu153 (2014).
CAS Article PubMed Google Scholar
Meletis, G. Carbapenem resistance: Overview of the problem and future perspectives. Ther. Adv. Infect. Dis. 3, 1521 (2015).
Google Scholar
Sands, K. et al. Characterization of antimicrobial-resistant Gram-negative bacteria that cause neonatal sepsis in seven low- and middle-income countries. Nat. Microbiol. 6, 512523 (2021).
PubMed PubMed Central Article CAS Google Scholar
Fonseca, F. et al. The basis for carbapenem hydrolysis by class A -lactamases: A combined investigation using crystallography and simulations. J. Am. Chem. Soc. 134, 1827518285 (2012).
CAS PubMed Article Google Scholar
Satyajeet, K. et al. Carbapenemresistant Enterobacteriaceae: Prevalence and bacteriological profile in a tertiary teaching hospital from rural western India. Indian J. Microbiol. Res. 2020, 7400 (2020).
Google Scholar
Wattal, C. et al. Impact of informational feedback to clinicians on antibiotic-prescribing rates in a tertiary care hospital in Delhi. Indian J. Med. Microbiol. 33, 255259 (2015).
CAS PubMed Article Google Scholar
Gupta, R., Malik, A., Rizvi, M. & Ahmed, M. Presence of metallo-beta-lactamases (MBL), extended-spectrum beta-lactamase (ESBL) & AmpC positive non-fermenting Gram-negative bacilli among Intensive Care Unit patients with special reference to molecular detection of bla(CTX-M) & bla(AmpC) genes. Indian J. Med. Res. 144, 271275 (2016).
CAS PubMed PubMed Central Article Google Scholar
Rohit, A. et al. CTX-M type extended-spectrum & #946;-lactamase in Escherichia coli isolated from extra-intestinal infections in a tertiary care hospital in south India. Indian J. Med. Res. 149, 281284 (2019).
CAS PubMed PubMed Central Article Google Scholar
Muzaheed, et al. High prevalence of CTX-M-15-producing Klebsiella pneumoniae among inpatients and outpatients with urinary tract infection in Southern India. J. Antimicrob. Chemother. 61, 13931394 (2008).
CAS PubMed PubMed Central Article Google Scholar
Devi, L. et al. Increasing prevalence of Escherichia coli and Klebsiella pneumoniae producing CTX-M-type extended-spectrum beta-lactamase, carbapenemase, and NDM-1 in patients from a rural community with community acquired infections: A 3-year study. Int. J. Appl. Basic Med. Res. 10, 156163 (2020).
CAS PubMed PubMed Central Article Google Scholar
Khan, E. R. et al. Prevalence and molecular epidemiology of clinical isolates of Escherichia coli and Klebsiella pneumoniae harboring extended-spectrum beta-lactamase and carbapenemase genes in Bangladesh. Microb. Drug Resist. 24, 15681579 (2018).
CAS PubMed Article Google Scholar
Rocha, F. R., Pinto, V. P. T. & Barbosa, F. C. B. The spread of CTX-M-type extended-spectrum -lactamases in Brazil: A systematic review. Microb. Drug Resist. 22, 301311 (2015).
PubMed Article CAS Google Scholar
Xia, S. et al. Dominance of CTX-M-type extended-spectrum -lactamase (ESBL)-producing Escherichia coli isolated from patients with community-onset and hospital-onset infection in China. PLoS ONE 9, e100707e100707 (2014).
ADS PubMed PubMed Central Article CAS Google Scholar
Abrar, S. et al. Distribution of blaCTX M, blaTEM, blaSHV and blaOXA genes in extended-spectrum--lactamase-producing clinical isolates: A three-year multi-center study from Lahore, Pakistan. Antimicrob. Resist. Infect. Control 8, 80 (2019).
PubMed PubMed Central Article Google Scholar
Zeynudin, A. et al. Prevalence and antibiotic susceptibility pattern of CTX-M type extended-spectrum -lactamases among clinical isolates of gram-negative bacilli in Jimma, Ethiopia. BMC Infect. Dis. 18, 524 (2018).
CAS PubMed PubMed Central Article Google Scholar
Yuki, S. et al. Environmental presence and genetic characteristics of carbapenemase-producing enterobacteriaceae from hospital sewage and river water in the Philippines. Appl. Environ. Microbiol. 86, e01906-e1919 (2021).
Google Scholar
Marie-Frdrique, L. et al. Extended-spectrum -lactamases of the CTX-M type now in Switzerland. Antimicrob. Agents Chemother. 51, 28552860 (2007).
Article CAS Google Scholar
Quinteros, M. et al. Extended-Spectrum -lactamases in enterobacteriaceae in Buenos Aires, Argentina, Public Hospitals. Antimicrob. Agents Chemother. 47, 28642867 (2003).
CAS PubMed PubMed Central Article Google Scholar
Al Naiemi, N. et al. Widely distributed and predominant CTX-M extended-spectrum -lactamases in Amsterdam, The Netherlands. J. Clin. Microbiol. 44, 30123014 (2006).
CAS PubMed PubMed Central Article Google Scholar
Zhao, W.-H. & Hu, Z.-Q. Epidemiology and genetics of CTX-M extended-spectrum -lactamases in Gram-negative bacteria. Crit. Rev. Microbiol. 39, 79101 (2013).
CAS PubMed Article Google Scholar
Pokhrel, R. H., Thapa, B., Kafle, R., Shah, P. K. & Tribuddharat, C. Co-existence of beta-lactamases in clinical isolates of Escherichia coli from Kathmandu, Nepal. BMC Res. Notes 7, 694 (2014).
PubMed PubMed Central Article CAS Google Scholar
Laurent, P., de la Ortiz, R.J.-M., Anas, R., Marta, A.-S. & Patrice, N. CTX-M-33 Is a CTX-M-15 derivative conferring reduced susceptibility to carbapenems. Antimicrob. Agents Chemother. 63, e01515-19 (2021).
Google Scholar
Walsh, T. R. Emerging carbapenemases: A global perspective. Int. J. Antimicrob. Agents 36, S8S14 (2010).
CAS PubMed Article Google Scholar
Nachimuthu, R. et al. Characterization of carbapenem-resistant Gram-negative bacteria from Tamil Nadu. J. Chemother. 28, 371374 (2016).
CAS PubMed Article Google Scholar
Kazi, M. et al. Molecular characterization of carbapenem-resistant Enterobacteriaceae at a tertiary care laboratory in Mumbai. Eur. J. Clin. Microbiol. Infect. Dis. 34, 467472 (2015).
CAS PubMed Article Google Scholar
Okoche, D., Asiimwe, B. B., Katabazi, F. A., Kato, L. & Najjuka, C. F. Prevalence and characterization of carbapenem-resistant enterobacteriaceae isolated from Mulago National Referral Hospital, Uganda. PLoS ONE 10, e0135745 (2015).
PubMed PubMed Central Article CAS Google Scholar
Mushi, M. F., Mshana, S. E., Imirzalioglu, C. & Bwanga, F. Carbapenemase genes among multidrug resistant gram negative clinical isolates from a Tertiary Hospital in Mwanza, Tanzania. Biomed Res. Int. 2014, 303104 (2014).
PubMed PubMed Central Article CAS Google Scholar
Hornsey, M., Phee, L. & Wareham, D. W. A novel variant, NDM-5, of the New Delhi metallo--lactamase in a multidrug-resistant Escherichia coli ST648 isolate recovered from a patient in the United Kingdom. Antimicrob. Agents Chemother. 55, 59525954 (2011).
CAS PubMed PubMed Central Article Google Scholar
Liang, W. et al. Emergence and mechanism of carbapenem-resistant Escherichia coli in Henan, China, 2014. J. Infect. Public Health 11, 347351 (2018).
PubMed Article Google Scholar
Kopotsa, K., Sekyere, J. O. & Mbelle, N. Characterization of plasmids mediating carbapenem-resistance in Klebsiella pneumoniae in Pretoria, South Africa. Int. J. Infect. Dis. 101, 14 (2020).
Article Google Scholar
Mmatli, M., Mbelle, N. M., Maningi, N. E. & Osei Sekyere, J. Emerging transcriptional and genomic mechanisms mediating carbapenem and polymyxin resistance in enterobacteriaceae: A systematic review of current reports. mSystems 5, e007830 (2020).
Article Google Scholar
Rawat, D. & Nair, D. Extended-spectrum & #223;-lactamases in gram negative bacteria. J. Glob. Infect. Dis. 2, 263274 (2010).
PubMed PubMed Central Article Google Scholar
See original here:
Genome-wide identification of carbapenem-resistant Gram-negative bacterial (CR-GNB) isolates retrieved from hospitalized patients in Bihar, India |...
Posted in Genome
Comments Off on Genome-wide identification of carbapenem-resistant Gram-negative bacterial (CR-GNB) isolates retrieved from hospitalized patients in Bihar, India |…
Alternative Medicine | Different Types Of Alternative Medicines
Posted: at 4:40 am
Alternative Medicine often referred to as integrative, or complementary medicine, including a wide range of medical treatments, products, practices, and health care systems that are not a part of standard/ conventional medical care. Alternative medicine is categorized together with complementary medicine and called complementary and alternative medicine (CAM). Worldwide a significant number of people irrespective of their education, age, and status rely on various forms of alternative medicine to treat or ameliorate disease. Alternative Medicine which follows whole body care approach are generally less expensive and uses natural products such as oils, herbs, metals, and minerals.
As per the study conducted by John A. Astin, education and poorer health status may predict alternative medical use. Sometimes people refer to alternatives healthcare as these medicines are more identical and coinciding with their own values, beliefs, and philosophical orientations toward health and life. The people with poorer health status refer to alternative medical use if the traditional healthcare system is unable to address their present healthcare need adequately, Similarly the lack of pathophysiological explanation for some disease, higher costs and number of tests and visiting different practitioners, often leads people to seek out Alternative Medicine as a treatment option.
As per the study conducted by the National Center for Complementary and Alternative Medicine (NCCAM) , about 38 percent of U.S. adults and about 12 percent of children are using some form of alternative medicine. Alternative medicines encompass a wide range of medicines practices, some of the most commonly used Alternative Medicine includes:
Developed in the late 18th century by Samuel Hahnemann, Homeopathy is an alternative medical system that is based on the belief that the body can cure itself. In Homeopathy the patient uses a dilute amount of natural substances, like plants and minerals to treat various ailments. It is most common in European countries. As per the National Health Interview Survey (NHIS) (2012), in Americans, an estimated 5 million adults and 1 million children used homeopathy in the previous year.
Homeopathy believes in like cures like treatment concept that suggests that a disease can be treated or cured by a substance that produces similar symptoms in healthy people. Homeopathy is in use for a wide range of health conditions such as dermatitis, depression, migraines, irritable bowel syndrome, hay fever, rheumatoid arthritis, high blood pressure, allergies, and many others.
However, there are some issues pertaining to the use of Homeopathy products. Homeopathy products lack scientific evidence and efficacy. In the past few years, certain European countries and the US have raised certain questions about the effectiveness and risk associated with Homeopathy products on their citizens health.
Naturopathy evolved as Alternative medicine in Europe during the 19th century. Naturopathy/ naturopathic medicine is a combination of traditional practices and health care approaches based on vitalism, folk medicine, the healing power of nature, and many others.
The Naturopathy consists of a wide range of non-invasive techniques such as herbal medicine (Herbalism), hydrotherapy (water therapy), physical therapies (which includes massage, bowen, and acupressure), nutrition and dietary modifications, homeopathic medicine, kinesiology, hygiene therapy, and nature cure. Naturopathy also employs other practices such as meditation, stress management, and relaxation. Today Naturopathy is practiced in many countries and is regulated by the government and authorities.
Originated in India about more than 3,000 years ago, Ayurveda (Indian medical system) is a natural system of medicine that relies on a natural or holistic approach to physical, mental, and spiritual well being. Ayurveda as a treatment is a combination of products derived from plants, animals, metals, minerals, or other materials along with maintaining diet, exercise, and a better lifestyle.
The Ayurvedic approaches are used for the treatment of diseases and conditions such as pain, rheumatoid arthritis, type 2 diabetes, ulcerative colitis, and many others. In some recently conducted studies, Ayurvedic medicine is found effective in relieving cancer symptoms.
Ayurvedic medicine is mainly practiced in countries such as India, Nepal, and Sri Lankan. The main research and development activities related to Ayurvedic medicine is limited to these countries only. Outside the Indian subcontinent, Ayurvedic medicine has very little popularity.
Unani medicine is an alternative medicine system, originated in Greece about 2500 years back, presently practiced in the Middle- East and South-Asian countries. Unani Medicine considers the human body as a single unit and aimed at treating the body, mind, and soul.
Unani medicine follows various practices to deal with health and disease using herbal remedies, dietary practices, and various alternative therapies. Among all the practices the main focus of Unani medicine on the diet and the state of digestion. Unani medicine offers treatment options to all the systems and organs of the human body such as musculoskeletal, skin, liver, and immunology. Some recent studies on animals have suggested that Unani medicine is beneficial for Brain Health, Arthritis, and Cataracts.
Acupuncture is a Traditional Chinese medicine practice, which focuses on stimulating specific points on the human body, most often thin needles are inserted through the skin.
Studies have suggested that acupuncture is helpful in relieving pain such as neck pain, headache, back pain, and knee pain. Apart from controlling pain Acupuncture is helpful in treating illnesses and ailments such as nausea, vomiting, fatigue, hot flashes, xerostomia, neuropathy, anxiety, depression, and sleeping problems.Acupuncture is beneficial as it has very limited side effects, and it is also safe (provided performed correctly). However, in certain cases, Acupuncture can cause complications and effects on the human body such as infections, bleeding, bruising, injury to the organ and central nervous system.
Countries follow different laws and regulations for acupuncture practices. In some countries like the USA acupuncture needles are considered as medical devices, and in some insurance providers have started covering acupuncture as medical treatment.
Apart from these Siddha, some other most common Types of Alternative Medicine include chiropractic, aromatherapy, meditation, and others. Besides healing disease and illness, the Alternative Medicines are helpful in providing relaxation, increasing the energy levels of the body, improvement in posture and balance, treating some eating disorders, relieving stress and anxiety, pain relief, strengthening the immune system, and overall health & wellbeing. These Alternative Medicines are followed and practiced worldwide. However, the use of Alternative medicines is surrounded by several challenges and issues.
Alternative medicine consists of diverse theories and practices, which lack scientific evidence and outcomes. The standard/ conventional medical system is based on clinical trials and research methods that aim to provide safe and effective medical care, while alternative treatments lack solid research for its use and practice.
Sometimes the use of alternative medicine can be dangerous and life-threatening as all of these are not 100 percent proven treatments, also these therapies lack the standard guideline, potential side effects, and dosage intake. Similarly, in some countries due to issues regarding safety and efficacy, Alternative therapies are not approved by their health and regulatory authorities.
To combat the issues and challenges in Alternative medicine use, several steps are being taken. Worldwide, many doctors, scientists, and researchers are studying the method and use of Different Types of Alternative Medicine, which is helping them in gaining knowledge and understanding about these medicines. Some of the Alternative Medicines such as acupuncture, homeopathy, and Ayurveda are gaining popularity in western countries, more and more people are looking for these medicines for some diseases and illnesses such as back pain.
The Different Types of Alternative Medicine have different benefits and drawbacks, but all of them have the same goal that is to attain good health and wellbeing. The choice of Alternative Medicine may vary from person to person, his knowledge, and also the type of disease or illness he is suffering from. With the rising awareness, the demand for Alternative Medicine is expected to grow in newer geographies. In the USA, Accredited Naturopathic colleges and universities are offering courses and medical training in alternative medicine. While in some countries like India, several alternative systems of medicines have been approved and regulated by the government for the past few decades. These medical practices are co-existing and integrated into the healthcare system of the country over the years and providing benefits to a large number of people.
Continue reading here:
Alternative Medicine | Different Types Of Alternative Medicines
Posted in Alternative Medicine
Comments Off on Alternative Medicine | Different Types Of Alternative Medicines
The Physician Shortage, Part Two: Keeping the Doors Open with Concierge Medicine – Medical Economics
Posted: at 4:40 am
For concierge medicine physicians, while the pandemic was difficult and demanding, their professional survivability was never in question.
In Part One, we described the role concierge medicine plays in extending the active years of experienced, dedicated doctors and helping to significantly ease the looming physician shortage. Now we consider how concierge medicine has sustained the practices of independent primary care physicians who are rapidly becoming a vanishing breed in the U.S.
Among the pandemics many heartbreaking statistics is this one: In 2020 and 2021, more than 24,000 independent practices were reported permanently or temporarily closed. We now have an even clearer picture of the pandemics impact on private practitioners with new data from Avalere and the Physicians Advocacy Institute (PAI) showing that almost three quarters of U.S. doctors now work for hospitals, health systems or corporate entities. That represents an almost 20% jump since 2019.
"COVID-19 drove physicians to leave private practice for employment at an even more rapid pace than we've seen in recent years," according to Kelly Kenney, chief executive officer of PIA. This study underscores the fact that physicians across the nation are facing severe burnout and strain. Between the financial stress that the pandemic had on practices, because they certainly had little revenue for a while, and the stress that physicians have felt mentally, you can't overstate that."
While a sense of normalcy is thankfully returning to everyday life, for primary care physicians in traditional fee-for-service practices, the situation remains bleak. According to the most recent Primary Care Collaborative survey, more than half of physician say primary care is crumbling, over 40% report describe themselves as mentally and financially fragile, one third report they are currently denied and/or seriously overdue payments from insurers and health plans, and only 21% find the fee-for-service form of payment sufficient.
We have long understood that the traditional fee-for-service payment model is simply not sustainable. Consider that since 2001, Medicare physician payment has fallen 20%, adjusted for inflation, while the cost of running a medical practice has increased 39% in that same time period. Becoming a hospital-employed physician doesnt provide a neatly packaged solution either. As reported in a recent Forbes article, after acquiring a physician practice, prices for healthcare services increase by 14% and hospital revenues rise by nearly 20%. However, most physicians are not benefiting, but are in fact, earning 20% less than independent practitioners, according to a 2022 Medscape survey.
Most troubling, as a result of the myriad challenges with seemingly no end, 25% of the physicians surveyed by the Primary Care Collaborative expect to leave primary care in the next three years. A December 2021AMA surveyalso reported that one in five physicians said they would likely leave their current practice within two years. The impact of this physician exodus is an incalculable loss that will be felt for many years to come.
However, for concierge medicine physicians, while the pandemic was difficult and demanding, their professional survivability was never in question. A stunning zero percent of concierge medical practices were closed during the pandemic, and they continue to thrive in 2022, based on a solid foundation of revenues driven by membership fees. Freed from financial worries and overloaded patient panels, concierge physicians not only keep their doors open, but their minds and hearts as well.
At Specialdocs I am gratified that we are able to offer a remarkably effective solution with proven resilience throughout two decades of relentless change. Below is a sampling of comments from our physician clients who sustained their practices and restored their passion for patient care with a thoughtful transition to our membership medicine model.
Dr. N.M., Atlanta, GA: Before I made the change, I was burned out to the point where I knew I was done with medicine if this didnt work. I was so frustrated with the way things had continued to worsen over the last 15 years - I didnt want to end up like the proverbial lobster in a pot of gradually heated water that doesnt realize its being cooked until it was too late. Now I have a completely different practice and life and I cant imagine ever going back to the way things were.
Dr. M.S., Burbank, CA: My traditional practice had grown to the level where I was responsible for almost 4,000 patients and I was drowning. Appointments were always rushed and there was never enough time. I felt that it was inevitable that I was going to miss something or make a mistake and neglecting my personal health and family life was the price I was paying.Concierge medicine was, and still is, the best way to achieve a work-life balance that is rarely seen in a primary care practice.
Dr. I.K., Petoskey, MI: Despite surging demand for rheumatology specialty care, my private practice had become too challenging to sustain. The paperwork and administrative burdens for a solo rheumatologist had mushroomed in the last decade, requiring an inordinate amount of time for prior authorizations, step therapy and electronic health record documentation; concurrently reimbursements continued to decline. I recognize that while it may not be the answer for every doctor, changing to the concierge medicine model with Specialdocs was the only viable alternative to permanently closing my practice doors. It has proven to be a tremendous fit for my career. Patients are now able to get an appointment the same or next day. We have unrushed visits that are conducive to incorporating beneficial integrative medicine modalities such as dietary, exercise, and mind-body approaches as appropriate, in addition to state-of-the-art treatment. I also have more time to coordinate care and give patients prompt feedback on lab and study results. From the first night of transition, I was able to sleep well, knowing my patients were being better served, my staff was happier, and that I could continue to practice in a time of great change and challenge for rheumatology.
Dr. Z.C., Nanuet, NY:My change to concierge medicine early in 2020 was precipitated by years of practicing like a hamster on a particularly relentless wheel, seeing up to 40 patients each day, with non-stop calls and endless paperwork afterward. Among several, mostly unpalatable options, including employment by a hospital, grinding it out until retirement or leaving the profession altogether, only the change to a concierge medical practice offered a workable solution for me. Had I not begun my concierge practice shortly before the pandemic started, I would have been totally unprepared to face an empty waiting room and a dramatic drop-off in office visits. Even more importantly, my patients would not have received the unlimited time and attention I was profoundly thankful to provide.
Dr. B.B., Brookline, MA: Making the change to concierge medicine saved our entire organization, including many who had worked with us for their entire careers. In 2020, it became increasingly clear that the pandemic was going to result in our shuttering the practice. I was compelled to find a way to reinvent ourselves and preserve the practice we had built with the utmost care for more than 25 years. Our transition with Specialdocs allows us to offer an approach that benefits patients enormously with time to focus on non-invasive treatments, prevention and wellnessand has restored our joy in practicing medicine.
Terry Bauer is CEO ofSpecialdocs,a concierge medicine pioneer that has transformed physicians professional lives since 2002, empowering them to deliver personalized patient care
Original post:
The Physician Shortage, Part Two: Keeping the Doors Open with Concierge Medicine - Medical Economics
Posted in Alternative Medicine
Comments Off on The Physician Shortage, Part Two: Keeping the Doors Open with Concierge Medicine – Medical Economics
QC Kinetix (Academy) is a Tucson Regenerative Medicine Clinic offering Alternative Treatments for Joint Pain – Digital Journal
Posted: at 4:40 am
Tucson, AZ Regenerative medicine contains a broad category of non-surgical therapies that aim to stimulate the healing/repair of damaged tissue. To explore the solutions, individuals can visit QC Kinetix (Academy), a Tucson-based regenerative medicine clinic with the mission of providing natural pain treatments and restorative therapies. The Pain control clinic comprises a team of medical providers committed to improving the quality of life of their patients, allowing them to resume performing normal chores, playing with their children, or training for marathons.
The team utilizes minimally invasive procedures, natural treatment protocols, and advanced medical technology to improve pain, decrease inflammation, and repair degenerated tissues. With the knowledge that joint pain/musculoskeletal injuries are frustrating to deal with, the team provides personalized services throughout a patients clinical experience. They treat patients with the highest level of service and respect while also educating them about their pain, conditions, treatment options, and the most appropriate regenerative therapies.
Sports injuries are commonly treated/managed with rest, ice, compression, elevation, medication, surgery, steroids, or physical therapy. While they may get a patient through their injuries, regenerative medicine may prove to be a better option since it takes advantage of the bodys natural healing capabilities. The alternative therapies offer relief from tennis elbow, torn Achilles tendon, knee pain, golfers elbow, shoulder pain, tendon/ligament tears, ankle pain, torn rotator cuff, wrist pain, and low back pain. QC Kinetix (Academy) integrates traditional sports treatments with regenerative medicine to help athletes, weekend warriors, or avid adventurers recover quickly. This approach also strengthens existing tissues and reduces the risk of future injuries.
Most people in Tucson suffer from conditions that affect the ligaments, muscles, bones, and tendons as a result of trauma, jerking movements, falls/sprains, repetitive movements, or overuse. When traditional treatments for musculoskeletal pain such as painkillers, anti-inflammatories, massage, or physical therapy fail to provide the relief a patient needs, they can visit the regenerative medicine clinic for Tucson back pain treatment, low back pain treatment, and tendon/muscle/ligament pain treatment solutions.
Additionally, QC Kinetix (Academy) slows down the progression of arthritis pain using a variety of treatment methods that use the bodys existing healing mechanisms to decrease pain without invasive surgical procedures, medication, or extensive physical therapy. Many patients have discovered the clinic while searching for long-term solutions for inflamed, irritated, and worn-down cartilage, connective tissues, and bones caused by arthritis pain.
A first visit to the clinic includes a thorough examination where a provider evaluates a patients overall health history, goals, and needs before determining the most suitable alternative treatments for their joint pain or musculoskeletal injuries. Learn more about their Tucson office by calling (520) 497-4955 or visiting the clinics website. QC Kinetix (Academy) is located at 310 N Wilmot Rd, Suite 101, Tucson, AZ, 85711, US.
Media Contact
Company NameQC Kinetix (Academy)Contact NameScott HootsPhone(520) 497-4955Address310 N Wilmot RdSuite 101CityTusconStateAZPostal Code85711CountryUnited StatesWebsitehttps://qckinetix.com/tucson/academy
Read the original post:
Posted in Alternative Medicine
Comments Off on QC Kinetix (Academy) is a Tucson Regenerative Medicine Clinic offering Alternative Treatments for Joint Pain – Digital Journal
European Commission Approves KEYTRUDA (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Adjuvant Monotherapy After Surgery…
Posted: at 4:40 am
DetailsCategory: AntibodiesPublished on Wednesday, 25 May 2022 09:50Hits: 58
Approval based on event-free survival benefit demonstrated in Phase 3 KEYNOTE-522 trial
This KEYTRUDA combination is the first immunotherapy option approved in the EU for high-risk early-stage TNBC
Decision marks fifth approval for KEYTRUDA in a breast or gynecologic cancer in the EU in less than one year
RAHWAY, NJ, USA I May 24, 2022 I Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the European Commission has approved KEYTRUDA, Mercks anti-PD-1 therapy, in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery for adults with locally advanced or early-stage triple-negative breast cancer (TNBC) at high risk of recurrence.
The approval is based on results from the pivotal Phase 3 KEYNOTE-522 trial, in which KEYTRUDA in combination with chemotherapy before surgery and continued as a single agent after surgery prolonged event-free survival (EFS), reducing the risk of EFS events or death by 37% (HR=0.63 [95% CI, 0.48-0.82]; p=0.00031) compared to neoadjuvant chemotherapy alone in this patient population. Median follow-up time for all patients was 37.8 months (range, 2.7-48).
KEYNOTE-522 was the first large, randomized Phase 3 study to report a statistically significant and clinically meaningful EFS result among patients with stage II and III TNBC. With this decision, this KEYTRUDA combination becomes the first immunotherapy option approved for patients in the European Union (EU) in this setting.
Triple-negative breast cancer has a high risk of recurrence within the first five years, so its meaningful for patients to have access to new therapies that can reduce the risk of disease progression, said Dr. Peter Schmid, lead, Centre for Experimental Cancer Medicine, Barts Cancer Institute in London, England. The approval of this KEYTRUDA regimen marks a turning point for patients with high-risk early-stage TNBC, as they now have an immunotherapy option in early stages of the disease that has demonstrated significant improvements in pathological complete response and event-free survival compared to neoadjuvant chemotherapy.
The safety of KEYTRUDA plus chemotherapy has been evaluated in 3,123 patients across tumor types. The incidence of Grade 3-5 adverse reactions in patients with TNBC was 80% for KEYTRUDA plus chemotherapy and 77% for chemotherapy.
KEYTRUDA was first approved in Europe to address an unmet need in certain patients with metastatic TNBC, and todays approval extends the use of KEYTRUDA to more patients facing this difficult-to-treat cancer this time in earlier stages of TNBC, said Dr. Gursel Aktan, vice president, global clinical development, Merck Research Laboratories. We are very proud that todays approval marks the fifth indication for KEYTRUDA in Europe for patients with breast or a gynecological cancer, an important area where patients need continued research and innovation.
This approval allows marketing of this KEYTRUDA regimen in all 27 EU member states plus Iceland, Lichtenstein, Norway and Northern Ireland. This is the second indication for KEYTRUDA in breast cancer in Europe. In October 2021, KEYTRUDA plus chemotherapy was approved for the first-line treatment of certain patients with locally recurrent unresectable or metastatic TNBC.
Merck is committed to delivering meaningful advances in gynecologic and breast cancers to patients around the world through its extensive clinical development program across its oncology portfolio of investigational and approved medicines. Within just the last year, KEYTRUDA has been approved in Europe for five new indications across breast, cervical and endometrial cancers as monotherapy and in novel combinations.
About KEYNOTE-522
The approval was based on data from KEYNOTE-522 (ClinicalTrials.gov, NCT03036488), a randomized, double-blind Phase 3 trial. The dual primary endpoints were pathological complete response rate, defined as pathological stage ypT0/Tis ypN0 at the time of definitive surgery, and EFS, defined as the time from randomization to the time of first occurrence of either disease progression that precluded definitive surgery, a local/distant recurrence, a second primary cancer or death from any cause. A key secondary endpoint was overall survival. The study enrolled 1,174 patients who were randomized 2:1 to receive either:
About triple-negative breast cancer (TNBC)
Triple-negative breast cancer is the most aggressive type of breast cancer, which has the highest risk of recurrence within the first five years after diagnosis and is associated with worse outcomes compared to other forms of breast cancer. Approximately 10-15% of patients with breast cancer are diagnosed with TNBC. While some breast cancers may test positive for estrogen receptors, progesterone receptors or overexpression of human epidermal growth factor receptor 2 (HER2), TNBC tests negative for all three. Triple-negative breast cancer tends to be more common in people who are younger than 40 years of age, who are Black or who have a BRCA1 mutation.
About Mercks early-stage cancer clinical program
Finding cancer at an earlier stage may give patients a greater chance of long-term survival. Many cancers are considered most treatable and potentially curable in their earliest stage of disease. Building on the strong understanding of the role of KEYTRUDA in later-stage cancers, Merck is studying KEYTRUDA in earlier disease states, with approximately 20 ongoing registrational studies across multiple types of cancer.
About KEYTRUDA (pembrolizumab) injection, 100 mg
KEYTRUDA is an anti-programmed death receptor-1 (PD-1) therapy that works by increasing the ability of the bodys immune system to help detect and fight tumor cells. KEYTRUDA is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both tumor cells and healthy cells.
Merck has the industrys largest immuno-oncology clinical research program. There are currently more than 1,700 trials studying KEYTRUDA across a wide variety of cancers and treatment settings. The KEYTRUDA clinical program seeks to understand the role of KEYTRUDA across cancers and the factors that may predict a patient's likelihood of benefitting from treatment with KEYTRUDA, including exploring several different biomarkers.
Selected KEYTRUDA (pembrolizumab) Indications in the U.S.
Melanoma
KEYTRUDA is indicated for the treatment of patients with unresectable or metastatic melanoma.
KEYTRUDA is indicated for the adjuvant treatment of adult and pediatric (12 years and older) patients with stage IIB, IIC, or III melanoma following complete resection.
Non-Small Cell Lung Cancer
KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations.
KEYTRUDA, in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, is indicated for the first-line treatment of patients with metastatic squamous NSCLC.
KEYTRUDA, as a single agent, is indicated for the first-line treatment of patients with NSCLC expressing PD-L1 [tumor proportion score (TPS) 1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is:
KEYTRUDA, as a single agent, is indicated for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS 1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA.
Head and Neck Squamous Cell Cancer
KEYTRUDA, in combination with platinum and fluorouracil (FU), is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent head and neck squamous cell carcinoma (HNSCC).
KEYTRUDA, as a single agent, is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) 1] as determined by an FDA-approved test.
KEYTRUDA, as a single agent, is indicated for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy.
Classical Hodgkin Lymphoma
KEYTRUDA is indicated for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL).
KEYTRUDA is indicated for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy.
Primary Mediastinal Large B-Cell Lymphoma
KEYTRUDA is indicated for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after 2 or more prior lines of therapy.
KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy.
Urothelial Carcinoma
KEYTRUDA is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC):
Non-muscle Invasive Bladder Cancer
KEYTRUDA is indicated for the treatment of patients with Bacillus Calmette-Guerin-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.
Microsatellite Instability-High or Mismatch Repair Deficient Cancer
KEYTRUDA is indicated for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options.
This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. The safety and effectiveness of KEYTRUDA in pediatric patients with MSI-H central nervous system cancers have not been established.
Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer
KEYTRUDA is indicated for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC).
Gastric Cancer
KEYTRUDA, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma.
This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.
Esophageal Cancer
KEYTRUDA is indicated for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either:
Cervical Cancer
KEYTRUDA, in combination with chemotherapy, with or without bevacizumab, is indicated for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS 1) as determined by an FDA-approved test.
KEYTRUDA, as a single agent, is indicated for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS 1) as determined by an FDA-approved test.
Hepatocellular Carcinoma
KEYTRUDA is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.
Merkel Cell Carcinoma
KEYTRUDA is indicated for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC). This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.
Renal Cell Carcinoma
KEYTRUDA, in combination with axitinib, is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC).
KEYTRUDA is indicated for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.
Endometrial Carcinoma
KEYTRUDA, as a single agent, is indicated for the treatment of patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.
Tumor Mutational Burden-High Cancer
KEYTRUDA is indicated for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [10 mutations/megabase] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established.
Cutaneous Squamous Cell Carcinoma
KEYTRUDA is indicated for the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC that is not curable by surgery or radiation.
Triple-Negative Breast Cancer
KEYTRUDA is indicated for the treatment of patients with high-risk early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.
KEYTRUDA, in combination with chemotherapy, is indicated for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS 10) as determined by an FDA-approved test.
Mercks focus on cancer
Our goal is to translate breakthrough science into innovative oncology medicines to help people with cancer worldwide. At Merck, the potential to bring new hope to people with cancer drives our purpose and supporting accessibility to our cancer medicines is our commitment. As part of our focus on cancer, Merck is committed to exploring the potential of immuno-oncology with one of the largest development programs in the industry across more than 30 tumor types. We also continue to strengthen our portfolio through strategic acquisitions and are prioritizing the development of several promising oncology candidates with the potential to improve the treatment of advanced cancers. For more information about our oncology clinical trials, visit http://www.merck.com/clinicaltrials.
About Merck
At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit http://www.merck.com and connect with us on Twitter, Facebook, Instagram, YouTube and LinkedIn.
SOURCE: Merck
Original post:
Posted in Alternative Medicine
Comments Off on European Commission Approves KEYTRUDA (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Adjuvant Monotherapy After Surgery…